We believe that the foregoing presentation of these Non-GAAP financial measures will enable investors, analysts and readers of our financial statements to compare Non-GAAP measures with relevant GAAP measures in all periods presented. Any Non-GAAP financial measure used by us should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.
At September 30, 2008, a total of 135.1 million shares of common stock were outstanding and stock options were outstanding on 24.0 million shares of common stock. The principal amount of Pfizer's $25 million convertible note, issued in May 2006, is convertible into approximately 9.2 million shares of common stock. The $30 million principal amount of our 0% Convertible Senior Unsecured Notes, issued in January 2007, is convertible into approximately 11.9 million shares of common stock. Monogram separately announced today that the board of directors has approved a 6-to-1 reverse split of its common stock and that this would be implemented effective after the close of the markets on November 3, 2008. Adjusting for the reverse stock split, the common stock outstanding at September 30, 2008 will be reduced to approximately 22.5 million shares.
Conference Call Details
Monogram will host a conference call today at 4:30 p.m. Eastern Time.
To participate in the live teleconference please call (877) 604-9672, or
(719) 325-4896 for international callers, fifteen minutes before the
conference begins. Live audio of the call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. Access to live and archived audio of the
conference call will be available by fol
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved